<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162422">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984048</url>
  </required_header>
  <id_info>
    <org_study_id>Q-CROC-01</org_study_id>
    <nct_id>NCT00984048</nct_id>
  </id_info>
  <brief_title>Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer</brief_title>
  <official_title>Prospective Study to Identify Molecular Mechanisms of Clinical Resistance to Standard First-line Therapy in Patients With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quebec Clinical Research Organization in Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Terry Fox Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds de la Recherche en Santé du Québec</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter translational study to understand therapeutic resistance in patients
      undergoing first-line chemotherapy (FOLFOX/Avastin, or FOLFIRI/Avastin) for metastatic
      colorectal cancer. Tissue samples from liver metastasis will be collected and banked before
      the start of chemotherapy and at the time of progression. Additionally, blood samples will
      be drawn monthly and stored in the tissue biobank.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The major obstacle to the cure of cancer by pharmacological agents is resistance to these
      agents. Clinical responses of metastatic cancers to the most advanced chemotherapeutic
      agents usually range from 15 to 40%, indicating that intrinsic resistance, and acquired
      resistance occurs almost inevitably in those tumors that do respond. In patients with
      metastatic colorectal cancer, clinical resistance to a particular treatment is a clear
      endpoint (tumor growth), and is usually observed within 6-12 months of any given therapy.
      Thus, drug resistance and selecting appropriate therapeutic alternatives for drug-resistant
      cancer remain major dilemmas for oncologists.

      The current first-line treatment for metastatic colorectal cancer in Quebec and much of
      North America is a combination called FOLFOX (the fluoro-pyrimidine 5-FU given as a 46-hour
      infusion, folinic acid and oxaliplatin) in combination with bevacizumab (Avastin®). An
      alternative regimen of cytotoxic drugs, also used with Avastin®, is FOLFIRI, which simply
      replaces oxaliplatin with the topoisomerase inhibitor irinotecan. In the metastatic setting,
      studies have not demonstrated significant differences between the two regimens, such that
      decision-making lacks definitive tools.

      The objective of this study is to identify, in clinical samples, the molecular signature of
      clinically resistant colorectal cancer (CRC) patients for the most current and commonly used
      therapeutic agents. The goals of this study are two-fold. First, to build a biobank of blood
      and tissue specimens, prior to starting chemotherapy and at a determined time-point
      (progression of disease), from patients undergoing the same standard and well established
      first-line treatments (FOLFOX/bevacizumab or FOLFIRI/bevacizumab) for metastatic colorectal
      cancer. Second, to use state-of-the-art approaches by various collaborating laboratories to
      correlate clinical outcomes with molecular events that can be used to predict and
      circumscribe chemoresistance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in biomarkers in patients that have acquired clinical resistance.</measure>
    <time_frame>4 years</time_frame>
    <description>Liver needle core biopsies are obtained pre-treatment and at progression of disease from all patients. These are used to discover exploratory biomarkers of resistance to FOLFOX/bevacizumab and FOLFIRI/bevacizumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events relating to the liver biopsy procedure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX, XELOX or FOLFIRI +/- bevacizumab</arm_group_label>
    <description>Patients are scheduled to receive first-line treatment for metastatic disease. They should be receiving at least one component of either FOLFOX, XELOX or FOLFIRI regimen with or without bevacizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Needle core biopsies of liver metastasis</intervention_name>
    <description>No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.</description>
    <arm_group_label>FOLFOX, XELOX or FOLFIRI +/- bevacizumab</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Tumor tissue from a hepatic metastasis will be removed by needle core biopsy (NCB) obtained
      under radiologic guidance and will be flash-frozen. To obtain sufficient material for tissue
      banking, three needle core biopsies (NCB) will be removed from the same metastasis.
      Additionally, monthly whole blood samples will be collected, as well as plasma.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will be conducted in patients with a confirmed diagnosis of colorectal cancer
        with the presence of liver metastasis, who will be receiving first-line treatment
        (FOLFOX/bevacizumab or FOLFIRI/bevacizumab) for metastatic disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a histologically confirmed diagnosis of colorectal cancer, with at
             least one liver metastasis site available for biopsy.

          2. For patients with liver only disease, patients deemed not to be initially resectable

          3. Scheduled to receive first-line chemotherapy (FOLFOX/bevacizumab or
             FOLFIRI/bevacizumab) for metastatic disease.

          4. Measurable metastatic disease (at least one unidimensionally measurable lesion)
             present after planned biopsy of metastatic site(s).

          5. ECOG 0, 1 or 2.

          6. Life expectancy of 12 or more weeks.

          7. Age &gt; 18 years.

          8. Able to adhere to the study visit schedule and other protocol requirements.

          9. Normal coagulation profile (PT, PTT, INR).

        Exclusion Criteria:

          1. Patients with initially resectable liver only metastases

          2. Have received prior therapy for metastatic cancer. Prior adjuvant therapy is allowed.

          3. Inadequate or unusable tissue as the only tissue available for biopsy.

          4. Contraindication to any of the components of the the first-line chemotherapy regimen.

          5. Known brain metastases or meningeal disease.

          6. Female patients who are pregnant or breastfeeding.

          7. Concurrent treatment with other anti-cancer therapy (palliative radiation is allowed
             but patients must have a metastatic site available for re-biopsy that has not been
             irradiated).

          8. Abnormal coagulation profile, any anti-coagulant therapy.

          9. Known infection with HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Batist, MD</last_name>
    <role>Study Director</role>
    <affiliation>Jewish General Hospital, Segal Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mathilde Couetoux du Tertre, PhD</last_name>
    <phone>514-282-4523</phone>
    <phone_ext>207</phone_ext>
    <email>mcouetoux@qcroc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bieke Wilmsen</last_name>
      <phone>+32 16 340751</phone>
      <email>bieke.wilmsen@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Hans Prenen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency (BCCA)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrudula Avileli</last_name>
      <phone>(506) 857- 5669</phone>
      <email>Mrudula.Avileli@horizonnb.ca</email>
    </contact>
    <investigator>
      <last_name>Mohammed Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dr. Georges L. Dumont University Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Eve Gingras</last_name>
      <phone>(506) 862-3779</phone>
      <email>marie-eveg@canceratl.ca</email>
    </contact>
    <investigator>
      <last_name>Eve St-Hilaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suganthi Suren</last_name>
      <phone>(416) 480-5000</phone>
      <phone_ext>82192</phone_ext>
      <email>suganthi.suren@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Yoo-Joung Ko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Smith</last_name>
      <phone>416-586-8440</phone>
      <email>JanetSmith@mtsinai.on.ca</email>
    </contact>
    <investigator>
      <last_name>Ronald Burkes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amélie Valcourt</last_name>
      <phone>450-466-5000</phone>
      <phone_ext>3373</phone_ext>
      <email>amelie.valcourt@rrsss16.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Benoit Samson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darly Cham</last_name>
      <phone>514-252-3400</phone>
      <phone_ext>4670</phone_ext>
      <email>dcham.hmr@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Lucas Sideris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Notre-Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annie Lebrasseur</last_name>
      <phone>514 890-8000</phone>
      <phone_ext>24831</phone_ext>
      <email>annie.lebrasseur.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Mustapha Tefhé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayat Salman</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>31917</phone_ext>
      <email>ayat.salman@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Peter Metrakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Christodoulopoulos, PhD</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>3651</phone_ext>
      <email>rchristodoulopoulos@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Gerald Batist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Claude Joncas</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>48186</phone_ext>
      <email>marie-claude.joncas@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Linda Chin</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>42560</phone_ext>
      <email>linda.chin@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Thierry Alcindor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Sacré-Coeur</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Chagnon</last_name>
      <phone>514-338-2222</phone>
      <phone_ext>2816</phone_ext>
      <email>caroline.chagnon@crhsc.rtss.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Bernard Lespérance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St-Mary's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melania Cartillone</last_name>
      <phone>514-345-3511</phone>
      <phone_ext>3981</phone_ext>
      <email>melania.cartillone.chsm@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Dalfen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu du Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryse Gingras</last_name>
      <phone>418-691-5781</phone>
      <email>maryse.gingras@chuq.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Jones</last_name>
      <phone>418-691-1581</phone>
      <email>theresa.jones@chuq.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Felix Couture, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 30, 2016</lastchanged_date>
  <firstreceived_date>September 23, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Gerald Batist</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>FOLFIRI</keyword>
  <keyword>Avastin</keyword>
  <keyword>Metastases</keyword>
  <keyword>Liver</keyword>
  <keyword>Colon cancer</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Resistance</keyword>
  <keyword>Biobanking</keyword>
  <keyword>Colorectal cancer with unresectable metastases to the liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
